Navigation Links
Pharmasset Receives Notice of Allowance
Date:6/26/2008

ected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that the USPTO will withdraw the Notice of Allowance, adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... RATON, Fla. , Nov. 25, 2014 /PRNewswire/ ... entered into a multi-product ANDA agreement with Pii ... ) under which Breckenridge and Pii expect ... the terms of the agreement, Pii will develop, ... market and distribute the products under its own ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... Reportlinker.com announces that a new market research ... ENT Devices Market Outlook in Brazil to ... Diagnostic Devices http://www.reportlinker.com/p0259722/ENT-Devices-Market-Outlook-in-Brazil-to-2017---Hearing-Aid-Devices-and-Implants-and-Diagnostic-Devices.html ... to 2017 - Hearing Aid Devices and Implants ...
... 14, 2011 New 5-year data from the longest ... show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit ... year period, clinically significant augmentation occurred in 5.1% of ... and 3 mg/24h) and in 13.2% of patients receiving ...
Cached Medicine Technology:Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 2Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 3Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 4Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 5Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 6Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 7Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 8Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 9Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 10New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 2New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 3New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 4New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 5New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 6
(Date:11/27/2014)... and Caicos Islands; BWI (PRWEB) November 28, 2014 ... the Tuscany Resort in the Turks & Caicos. ... by TripAdvisor in Providenciales, is announcing a few highly ... bedroom villa rentals. And they are offering every ... , Additionally, The Tuscany, is having a January ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Luciana Lagana ... to be part of Omadox, a feature film that received ... an award for best ensemble cast. It is also an ... a great start to a successful cinematic career for James ... white movies. If you enjoy experimental mystery, filmed in glorious ...
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Tylenol lawsuits ... were allegedly injured by the medication are continuing to ... litigation is looking ahead to a status conference in ... a Scheduling Order issued earlier this year, a conference ... 16th at 10:00 a.m. Items likely to be discussed ...
Breaking Medicine News(10 mins):Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3
... shift workers or those with narcolepsy, scientists say , FRIDAY, ... called orexin-A may be key to undoing the negative mental ... , Orexin-A is a peptide (a kind of protein) made ... at the Wake Forest University School of Medicine in Winston-Salem, ...
... free online until March, presents key articles of interest to ... consider the history of leukemia, and how different ... children , describe new research based ... for treatment to target these sub-types more precisely ...
... State,s Highest Honor for Organizational Performance Excellence, ... Council (MQC) announces Oakwood Healthcare, Inc. as a ... Leadership Award is the highest honor for,organizational performance ... a,rigorous review by a team of examiners who ...
... J. Fox,Foundation has committed up to $3.8 million ... treat Parkinson,s disease by reducing expression,of the protein ... Farrer,PhD, of Mayo Clinic Jacksonville (Florida) with collaborators ... Center will work,to optimize a small interfering RNA ...
... Nurse-to-Patient Staffing Ratios, Ability for Nurses to ... Advocate for Urgent Patient Safety Measures, PHOENIX, Jan. 4 ... major legislation to,make Arizona hospitals safer for patients and strengthen ... patient protections., HB 2041, the Arizona Patient Protection Act, ...
... If index finger is shorter than ring finger you might be ... Women whose index finger is shorter than their ring finger are ... In fact, having a shorter index finger may double the risk ... , The ratio of index finger length to ring finger ...
Cached Medicine News:Health News:Protein Nasal Spray Revives Sleep-Deprived Monkeys 2Health News:Michigan Quality Council (MQC) Names Oakwood Healthcare Inc. 2007 State Quality Award Recipient 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 3Health News:Arizona Patient Protection Act Introduced 2Health News:Arizona Patient Protection Act Introduced 3Health News:Fingers Point to Risk for Arthritic Knees 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: